AG真人官方

Azitra, Inc. reported continuing pre鈥慶ommercial operations and clinical progress while facing significant financing pressure. For the six months ended June 30, 2025 the company recorded a net loss of $5.96 million, used $5.89 million of cash in operating activities and ended the period with $1.05 million of cash. Total assets declined to $3.96 million from $7.36 million at year-end 2024, and working capital was approximately $0.3 million, contributing to management's conclusion of substantial doubt about the company's ability to continue as a going concern.

The company advanced its development programs: ATR-12 dosed its first patient in August 2024 with initial safety results reported in H1 2025; ATR-04 received IND clearance and Fast Track designation and is expected to dose its first patient in Q3 2025; ATR-01 remains in lead optimization with an IND targeted for 2026. On April 24, 2025 Azitra established a $20 million equity line of credit (ELOC) with Alumni Capital, issued shares and warrants under the ELOC and reported gross proceeds of $1.7 million, with $18.3 million available under the facility as of August 11, 2025.

Azitra held its 2025 annual meeting on June 23, where stockholders voted on several key proposals. Three out of four proposals were concluded, while one remains pending:

• Board Elections: All four director nominees were successfully elected: Francisco D. Salva, Travis Whitfill, Barbara Ryan, and John Schroer, with each receiving over 1 million votes in favor
• Auditor Appointment: Stockholders ratified Grassi & Co., CPAs as the independent auditor for FY2025, with 8.37 million votes in favor
• Share Issuance: Approved issuance of >19.99% of outstanding common stock under purchase agreement with Alumni Capital LP, receiving 1.2 million favorable votes
• Pending Vote: Proposal to increase authorized common stock from 100M to 200M shares was adjourned to July 3, 2025, allowing additional time for stockholder voting

The company maintains its status as an emerging growth company and trades on NYSE American under symbol AZTR.

Azitra has filed a significant update regarding their 2025 Annual Meeting of Stockholders scheduled for June 23, 2025. The company has issued a supplement to their previously filed proxy statement, specifically addressing changes to the voting standard for Proposal 2.

The key proposal under consideration seeks stockholder approval to double the authorized common stock from 100,000,000 to 200,000,000 shares. This represents a material change to the company's capital structure that could significantly impact existing shareholders.

Key details:

• Annual Meeting to be held virtually on June 23, 2025, at 11:00 AM ET
• Original proxy statement filed May 29, 2025
• Supplementary proxy statement filed June 18, 2025
• Company maintains emerging growth company status

Stockholders are encouraged to review the complete proxy materials available on the SEC website before making voting decisions.

Azitra has filed a supplementary proxy statement (DEFA14A) to update voting requirements for their upcoming Annual Meeting on June 23, 2025. The key modification relates to Proposal 2, which seeks to increase authorized common stock from 100 million to 200 million shares.

Due to recent Delaware General Corporation Law amendments (Section 242(d)(2)), the voting standard has changed. The proposal now requires a majority of votes cast rather than a majority of outstanding shares. Key voting details:

• Abstentions will not count as votes "For" or "Against"
• Brokers have no discretionary voting authority
• Broker non-votes won't be counted as votes cast

Previously submitted proxies remain valid unless revoked. The Board unanimously recommends voting "FOR" all proposals. Shareholders can vote via Internet, telephone, or mail, and can change their votes through various methods including attending the virtual meeting on June 23, 2025.